Abl Bio Inc.

I-mab Biopharma US Limited

Yuhan Corporation

Eunyoung Park

Yangsoon Lee

Hyejin Chung

Eunsil Sung

Byungje Sung

Youngdon Pak

Lei Fang

Wenqing Jiang

Yeunju Kim

Kyeongsu Park

Yong-Gyu Son

Uijung Jung

Sang Hoon Lee

Eun-Jung Lee

Jinhyung Ahn

Donghoon Yeom

Kyungjin Park

Jaeho Jung

Daehae Song

Eunjung Kim

Ui-Jung Jung

Seawon Ahn

Weon-Kyoo You

Juhee Kim

Bingshi Guo

Zhengyi Wang

Moo Young Song

Na Rae Lee

Jiseon Yoo

Young Bong Park

Minji Park

Yeryoung Yong

Wonjun Son

YoungKwang Kim

Taewang Kim

Hyoju Choi

Sang-Jun Ha

Myeong Joon Kim

Chanmoo Lee

Junghyeon Hong

Yeun Ju Kim

Jun Hyun Jeong

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Anti-4-1BB antibody and use thereof

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof

Growing community of inventors

Seongnam-si, South Korea

Eunyoung Park